ArticleFrontiers in oncology2025
Navigating beyond the surface - prognostic significance of KRAS, NRAS, BRAF, PIK3CA, and TP53 mutations examined by exons.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Analysis of PIK3CA mutation prevalence variation among colorectal cancer populations: a comprehensive review.Molecular biology reports · 2025Pooled it
- Molecular Profiling of KRAS, NRAS, and BRAF in Colorectal Cancer: Insights From a Libyan Cohort.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metastatic colorectal cancer (mCRC) is a disease with various molecular profiles that exhibit different evolution patterns. Although most mCRC patients receive the same chemotherapy drugs in the first-line setting, treatment response is heterogeneous suggesting some tumors are inherently resistant to oxaliplatin/fluoropyrimidine regimen. Genomic-based markers may help identify these patients and guidetreatment decisions due to potential prognostic and predictive value. Methods: We performed a retrospective analysis on 77 patients diagnosed with mCRC treated with an oxaliplatin/fluoropyrimidine regimen in the Regional Institute of Oncology Iaşi between April 2017 and December 2019. We studied the impact of KRAS, NRAS, BRAF, PIK3CA and TP53 genes and their mutations in a treatment-naive population. Results: The median progression free survival (PFS) was 11 months (95% CI, 10.2-11.7 months) and the median overall survival (OS) was 23.6 months (16.3-30.8 months). Multivariate analysis of factors affecting PFS revealed that KRAS exon -3 mutation was associated with quicker progression while on oxaliplatin-based chemotherapy. A similar analysis indicated that the KRAS exon -3 mutation was also associated with decreased OS (p=0.03). The presence of the TP53 in exon 8 was associated with an increased OS (p=0.001). Discussion: The present analysis offers insights into the prognostic implications of genes and exon-distributed mutations within RAS, BRAF, PIK3CA, and TP53 in mCRC. Subsequent prospective investigations with a more extensive patient cohort are needed to clarify the influence of exon-distributed mutations on therapeutic decision-making and prognostic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.